A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia

NCT06853444 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune Thrombocytopenia (ITP)

Interventions

DRUG: ESG206
DRUG: ESG206
DRUG: ESG206
DRUG: ESG206

Sponsor

Shanghai Escugen Biotechnology Co., Ltd